NCT06594211View on ClinicalTrials.gov

Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 9, 2024

Primary Completion Date

October 9, 2028

Study Completion Date

October 9, 2028

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL

ACT-001 CAR-NK cell

Subjects were distributed into three dosage groups, each receiving a single dose of CAR-NK cells at levels of 1×10\^8, 3×10\^8, and 9×10\^8 cells, respectively.

Trial Locations (1)

200127

Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai